The sole determinant of eligibility for immunotherapy in patients with NSCLC, is the existence of PD‐L1 molecule expression on cancer cells as identified by immunohistochemically17 (Figure 1). The gene discussed is CD274; the disease is non-small cell lung carcinoma.